Androgen deprivation therapy prevents bladder cancer recurrence

Oncotarget

Volumn 5, Issue 24, 2014, Pages 12665-12674

  Izumi, Koji ^a   Taguri, Masataka ^b   Miyamoto, Hiroshi ^c   Hara, Yoshinori ^d   Kishida, Takeshi ^e   Chiba, Kimio ^f   Murai, Tetsuo ^g   Hirai, Kotaro ^h   Suzuki, Kotaro ⁱ   Fujinami, Kiyoshi ^j   Ueki, Teiichiro ^k   Udagawa, Koichi ^l   Kitami, Kazuo ^m   Moriyama, Masatoshi ⁿ   Miyoshi, Yasuhide ^b   Tsuchiya, Futoshi ^o   Ikeda, Ichiro ^p   Kobayashi, Kazuki ^q   Sato, Maho ^b   Morita, Satoshi ^r   Noguchi, Kazumi ^b   Uemura, Hiroji ^a   more..

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Odawara Municipal Hospital   (Japan)

^e KANAGAWA CANCER CENTER   (Japan)

^f KAWASAKI MUNICIPAL HOSPITAL   (Japan)

^g International Goodwill Hospital   (Japan)

^h SAGAMIHARA NATIONAL HOSPITAL   (Japan)

ⁱ SAISEIKAI YOKOHAMASHI NANBU HOSPITAL   (Japan)

^j CHIGASAKI MUNICIPAL HOSPITAL   (Japan)

^k JAPANESE RED CROSS SOCIETY   (Japan)

^l Hiratsuka City Hospital   (Japan)

^m Fujisawa City Hospital   (Japan)

ⁿ YOKOHAMA MUNICIPAL CITIZEN'S HOSPITAL   (Japan)

^o YOKOHAMA CITY MINATO RED CROSS HOSPITAL   (Japan)

^p Yokohama Minami Kyosai Hospital   (Japan)

^q YOKOSUKA KYOSAI HOSPITAL   (Japan)

^r KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Androgen; Androgen deprivation therapy; Bladder cancer; Recurrence

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; ANDROGEN;

ADULT; AGE DISTRIBUTION; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BLADDER CANCER; BRACHYTHERAPY; CANCER GRADING; CANCER INCIDENCE; CANCER PATIENT; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARCINOMA IN SITU; COHORT ANALYSIS; CONTROLLED STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; RISK REDUCTION; SURVIVAL RATE; SURVIVAL TIME; TUMOR VOLUME; DEFICIENCY; DISEASE FREE SURVIVAL; FEMALE; METABOLISM; MIDDLE AGED; PREVENTION AND CONTROL; TUMOR RECURRENCE; URINARY BLADDER NEOPLASMS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANDROGENS; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS;

EID: 84921411550     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2851     Document Type: Article

References (32)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2013; 63:11-30.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69-90.
3. Shang PF, Kwong J, Wang ZP, Tian J, Jiang L, Yang K, Yue ZJ, Tian JQ. Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer. Cochrane database Syst Rev. 2011; CD006885.
4. Sievert KD, Amend B, Nagele U, Schilling D, Bedke J, Horstmann M, Hennenlotter J, Kruck S, Stenzl A. Economic aspects of bladder cancer: what are the benefits and costs? World J Urol. 2009; 27:295-300.
5. Hartge P, Harvey EB, Linehan WM, Silverman DT, Sullivan JW, Hoover RN, Fraumeni JF. Unexplained excess risk of bladder cancer in men. J Natl Cancer Inst. 1990; 82:1636-40.
6. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA. 2011; 306:737-45.
7. Miyamoto H, Yang Z, Chen Y-T, Ishiguro H, Uemura H, Kubota Y, Nagashima Y, Chang Y-J, Hu Y-C, Tsai M-Y, Yeh S, Messing EM, Chang C. Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst. 2007; 99:558-68.
8. Hsu J-W, Hsu I, Xu D, Miyamoto H, Liang L, Wu X-R, Shyr C-R, Chang C. Decreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor. Am J Pathol. 2013; 182:1811-20.
9. Li Y, Izumi K, Miyamoto H. The role of the androgen receptor in the development and progression of bladder cancer. Jpn J Clin Oncol. 2012; 42:569-77.
10. Miyamoto H, Yao JL, Chaux A, Zheng Y, Hsu I, Izumi K, Chang C, Messing EM, Netto GJ, Yeh S. Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. BJU Int. 2012; 109:1716-26.
11. Mir C, Shariat SF, van der Kwast TH, Ashfaq R, Lotan Y, Evans A, Skeldon S, Hanna S, Vajpeyi R, Kuk C, Alkhateeb S, Morote J, van Rhijn BWG, et al. Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. BJU Int. 2011; 108:24-30.
12. Zheng Y, Izumi K, Yao JL, Miyamoto H. Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells. Endocr Relat Cancer. 2011; 18:451-64.
13. Boorjian SA, Heemers HV, Frank I, Farmer SA, Schmidt LJ, Sebo TJ, Tindall DJ. Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder. Endocr Relat Cancer. 2009; 16:123-37.
14. Singer EA, Golijanin DJ, Miyamoto H, Messing EM. Androgen deprivation therapy for prostate cancer. Expert Opin Pharmacother. 2008; 9:211-28.
15. Akaza H, Usami M, Hinotsu S, Ogawa O, Kagawa S, Kitamura T, Tsukamoto T, Naito S, Hirao Y, Murai M, Yamanaka H. Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance. Jpn J Clin Oncol. 2004; 34:329-36.
16. Kinoshita Y, Singh A, Rovito PM, Wang CY, Haas GP. Double primary cancers of the prostate and bladder: a literature review. Clin Prostate Cancer. 2004; 3:83-6.
17. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol. 1983; 1:710-9.
18. Gakis G, Stenzl A. Gender-specific differences in muscleinvasive bladder cancer: the concept of sex steroid sensitivity. World J Urol. 2013; 31:1059-64.
19. Boorjian S, Cowan JE, Konety BR, DuChane J, Tewari A, Carroll PR, Kane CJ. Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol. 2007; 177:883-7; discussion 887-8.
20. Hsu I, Chuang K-L, Slavin S, Da J, Lim W-X, Pang S-T, O'Brien JH, Yeh S. Suppression of ERβ signaling via ERβ knockout or antagonist protects against bladder cancer development. Carcinogenesis. 2014; 35:651-61.
21. Hsu I, Yeh C, Slavin S, Miyamoto H, Netto GJ, Tsai Y, Muyan M, Wu X, Messing EM, Guancial EA, Yeh S. Estrogen receptor alpha prevents bladder cancer via INPP4B inhibited akt pathway in vitro and in vivo. Oncotarget. 2014; 5:7917-35.
22. Izumi K, Zheng Y, Li Y, Zaengle J, Miyamoto H. Epidermal growth factor induces bladder cancer cell proliferation through activation of the androgen receptor. Int J Oncol. 2012; 41:1587-92.
23. Hsieh T-F, Chen C-C, Ma W-L, Chuang W-M, Hung X- F, Tsai Y-R, Lin M-HA, Zhang Q, Zhang C, Chang C, Shyr C-R. Epidermal growth factor enhances androgen receptormediated bladder cancer progression and invasion via potentiation of AR transactivation. Oncol Rep. 2013; 30:2917-22.
24. Li Y, Zheng Y, Izumi K, Ishiguro H, Ye B, Li F, Miyamoto H. Androgen activates β-catenin signaling in bladder cancer cells. Endocr Relat Cancer. 2013; 20:293-304.
25. Lin C, Yin Y, Stemler K, Humphrey P, Kibel AS, Mysorekar IU, Ma L. Constitutive β-catenin activation induces male-specific tumorigenesis in the bladder urothelium. Cancer Res. 2013; 73:5914-25.
26. Izumi K, Zheng Y, Hsu J, Chang C, Miyamoto H. Androgen receptor signals regulate UDP-glucuronosyltransferases in the urinary bladder: A potential mechanism of androgeninduced bladder carcinogenesis. Mol Carcinog. 2013; 52:94-102.
27. Izumi K, Li Y, Ishiguro H, Zheng Y, Yao JL, Netto GJ, Miyamoto H. Expression of UDP-glucuronosyltransferase 1A in bladder cancer: Association with prognosis and regulation by estrogen. Mol Carcinog. 2014; 53:314-24.
28. Overdevest JB, Knubel KH, Duex JE, Thomas S, Nitz MD, Harding MA, Smith SC, Frierson HF, Conaway M, Theodorescu D. CD24 expression is important in male urothelial tumorigenesis and metastasis in mice and is androgen regulated. Proc Natl Acad Sci U S A. 2012; 109:E3588-96.
29. Sylvester RJ, van der Meijden APM, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DWW, Kurth K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006; 49:466-5; discussion 475-7.
30. Miyamoto H, Miller JS, Fajardo DA, Lee TK, Netto GJ, Epstein JI. Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system. Pathol Int. 2010; 60:1-8.
31. Nelson WB. Recurrent Events Data Analysis for Product Repairs, Disease Recurrences, and Other Applications Philadelphia, PA: SIAM; 2003.
32. Andersen PK, Gill RD. Cox's Regression Model for Counting Processes: A Large Sample Study. Ann Stat. 1982; 10:1100-20.